Advertisement

TIPS Indications and Contraindications—Pushing the Limits: Is Earlier Better?

  • José Ferrusquía-Acosta
  • Virginia Hernández-GeaEmail author
Management of Cirrhotic Patient (A Cardenas and P Tandon, Section Editors)
  • 4 Downloads
Part of the following topical collections:
  1. Topical Collection on Management of the Cirrhotic Patient

Abstract

Purpose of Review

To describe the main indications and contraindications of transjugular intrahepatic portosystemic shunt (TIPS) placement in patients with portal hypertension (PH).

Recent Findings

An adequate selection of patients helps to identify those who may benefit from TIPS in terms of survival. In patients with acute variceal bleeding and factors of poor prognosis, a pre-emptive use of TIPS is associated with significant reductions in treatment failure and mortality. Similarly, TIPS has shown to improve survival in a highly selected group of patients with cirrhosis and refractory ascites.

Summary

PH is a clinical syndrome associated with the appearance of certain complications which can lead to high morbidity and mortality. TIPS placement effectively reduces portal pressure improving the outcomes of patients who present severe and/or refractory complications of PH. However, an adequate selection of candidates seems to be a key factor for improving the outcomes of patients treated with TIPS.

Keywords

Portal hypertension Transjugular intrahepatic portosystemic shunt TIPS Variceal bleeding Refractory ascites Portal vein thrombosis Cirrhosis Esophageal varices 

Notes

Financial Support

This work was sponsored by the Instituto de Salud Carlos III (ISCIII) PI14/00182 and PI17/00298 and the European Union (Fondos FEDER, “Una manera de hacer Europa”). CIBERehd is funded by Instituto de Salud Carlos III.

Compliance with Ethical Standards

Conflict of Interest

José Ferrusquía-Acosta reports personal fees from GORE, outside the submitted work.

Virginia Hernández-Gea reports personal fees from GORE, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.  https://doi.org/10.1038/nrgastro.2009.149.CrossRefGoogle Scholar
  2. 2.
    Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61.  https://doi.org/10.1056/NEJMoa044456.CrossRefGoogle Scholar
  3. 3.
    Ripoll C, Groszmann R, Garcia–Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–8.  https://doi.org/10.1053/j.gastro.2007.05.024.CrossRefGoogle Scholar
  4. 4.
    Abraldes J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–8.  https://doi.org/10.1053/jhep.2003.50133.CrossRefGoogle Scholar
  5. 5.
    Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40:757–65.  https://doi.org/10.1016/j.jhep.2004.01.017.CrossRefGoogle Scholar
  6. 6.
    D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611–24.  https://doi.org/10.1053/j.gastro.2006.09.013.CrossRefGoogle Scholar
  7. 7.
    Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75.  https://doi.org/10.1053/j.gastro.2003.11.016.CrossRefGoogle Scholar
  8. 8.
    Hernández-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004;40:1197–202.  https://doi.org/10.1002/hep.20436.CrossRefGoogle Scholar
  9. 9.
    Thornburg B, Desai K, Hickey R, Kulik L, Ganger D, Baker T, et al. Portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: technical considerations. Tech Vasc Interv Radiol. 2016;19:52–60.  https://doi.org/10.1053/j.tvir.2016.01.006.CrossRefGoogle Scholar
  10. 10.
    Salem R, Vouche M, Baker T, Herrero JI, Caicedo JC, Fryer J, et al. Pretransplant portal vein recanalization—transjugular intrahepatic portosystemic shunt in patients with complete obliterative portal vein thrombosis. Transplantation. 2015;99:2347–55.  https://doi.org/10.1097/TP.0000000000000729.CrossRefGoogle Scholar
  11. 11.
    •• Thornburg B, Desai K, Hickey R, Hohlastos E, Kulik L, Ganger D, et al. Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort. J Vasc Interv Radiol. 2017;28:1714–1721.e2.  https://doi.org/10.1016/j.jvir.2017.08.005 This study analyzed the safety and efficacy of portal vein recanalization followed by TIPS in patients with cirrhosis and PVT as a procedure that aims to improve liver transplantation candidacy. CrossRefGoogle Scholar
  12. 12.
    D’Amico G. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599–612.  https://doi.org/10.1053/jhep.2003.50385.CrossRefGoogle Scholar
  13. 13.
    Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652–9.  https://doi.org/10.1002/hep.20339.CrossRefGoogle Scholar
  14. 14.
    Chau T, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. “Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology. 1998;114:981–7.  https://doi.org/10.1016/S0016-5085(98)00640-4.CrossRefGoogle Scholar
  15. 15.
    Azoulay D, Castaing D, Majno P, Saliba F, Ichaï P, Smail A, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35:590–7.  https://doi.org/10.1016/S0168-8278(01)00185-4.CrossRefGoogle Scholar
  16. 16.
    García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9.  https://doi.org/10.1056/NEJMoa0910102.CrossRefGoogle Scholar
  17. 17.
    Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40:793–801.  https://doi.org/10.1002/hep.20386.CrossRefGoogle Scholar
  18. 18.
    Garcia-Pagán JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58:45–50.  https://doi.org/10.1016/j.jhep.2012.08.020.CrossRefGoogle Scholar
  19. 19.
    Thabut D, Pauwels A, Carbonell N, Remy AJ, Nahon P, Causse X, et al. Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results. J Hepatol. 2018;68:73–81.  https://doi.org/10.1016/j.jhep.2017.09.002.CrossRefGoogle Scholar
  20. 20.
    • Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology. 2018.  https://doi.org/10.1002/hep.30182 This multicenter, international, observational study confirmed the survival benefit of TIPS in a large cohort of patients with cirrhosis and acute VB at high risk for treatment failure.
  21. 21.
    Lv Y, Zuo L, Zhu X, Zhao J, Xue H, Jiang Z, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study. Gut. 2018:gutjnl-2018-317057.  https://doi.org/10.1136/gutjnl-2018-317057.
  22. 22.
    Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology. 1999;30:612–22.  https://doi.org/10.1002/hep.510300316.CrossRefGoogle Scholar
  23. 23.
    Khan SA, Tudur Smith C, Williamson PR, Sutton R. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database Syst Rev. 2006:CD000553.  https://doi.org/10.1002/14651858.CD000553.pub2.
  24. 24.
    de Franchis R. Expanding consensus in portal hypertension. J Hepatol. 2015;63:743–52.  https://doi.org/10.1016/j.jhep.2015.05.022.CrossRefGoogle Scholar
  25. 25.
    Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35.  https://doi.org/10.1002/hep.28906.CrossRefGoogle Scholar
  26. 26.
    Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rössle M, Panther E, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology. 2015;149:660–668.e1.  https://doi.org/10.1053/j.gastro.2015.05.011.CrossRefGoogle Scholar
  27. 27.
    Holster IL, Tjwa ETTL, Moelker A, Wils A, Hansen BE, Vermeijden JR, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology. 2016;63:581–9.  https://doi.org/10.1002/hep.28318.CrossRefGoogle Scholar
  28. 28.
    Garcia–Pagán JC, Patch D. Trials and tribulations: the prevention of variceal rebleeding. Gastroenterology. 2015;149:528–31.  https://doi.org/10.1053/j.gastro.2015.07.026.CrossRefGoogle Scholar
  29. 29.
    Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38:69–89.  https://doi.org/10.1016/S0168-8278(03)00007-2.CrossRefGoogle Scholar
  30. 30.
    Rössle M. TIPS: 25 years later. J Hepatol. 2013;59:1081–93.  https://doi.org/10.1016/j.jhep.2013.06.014.CrossRefGoogle Scholar
  31. 31.
    Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988–1000.  https://doi.org/10.1136/gut.2009.193227.CrossRefGoogle Scholar
  32. 32.
    •• Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152:157–63.  https://doi.org/10.1053/j.gastro.2016.09.016 This study evaluates the use of TIPS using PTFE-covered stents in a selected population of patients with cirrhosis and refractory ascites. CrossRefGoogle Scholar
  33. 33.
    Barange K, Péron J-M, Imani K, Otal P, Payen J-L, Rousseau H, et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology. 1999;30:1139–43.  https://doi.org/10.1002/hep.510300523.CrossRefGoogle Scholar
  34. 34.
    Lo G-H, Liang H-L, Chen W-C, Chen M-H, Lai K-H, Hsu P-I, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy. 2007;39:679–85.  https://doi.org/10.1055/s-2007-966591.CrossRefGoogle Scholar
  35. 35.
    Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol. 2010;105:635–41.  https://doi.org/10.1038/ajg.2009.634.CrossRefGoogle Scholar
  36. 36.
    Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288–95.  https://doi.org/10.1136/gut.47.2.288.CrossRefGoogle Scholar
  37. 37.
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28:416–22.  https://doi.org/10.1002/hep.510280219.CrossRefGoogle Scholar
  38. 38.
    Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002;14:1363–8.CrossRefGoogle Scholar
  39. 39.
    Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, et al. Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: a matched cohort analysis. Am J Kidney Dis. 2016;68:381–91.  https://doi.org/10.1053/j.ajkd.2016.02.041.CrossRefGoogle Scholar
  40. 40.
    Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55–64.  https://doi.org/10.1002/hep.20262.CrossRefGoogle Scholar
  41. 41.
    Luca A, Caruso S, Milazzo M, Marrone G, Mamone G, Crinò F, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012;265:124–32.  https://doi.org/10.1148/radiol.12112236.CrossRefGoogle Scholar
  42. 42.
    Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253–1260.e4.  https://doi.org/10.1053/j.gastro.2012.07.018.CrossRefGoogle Scholar
  43. 43.
    Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108:568–74.  https://doi.org/10.1038/ajg.2012.452.CrossRefGoogle Scholar
  44. 44.
    Hibi T, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, et al. When and why portal vein thrombosis matters in liver transplantation. Ann Surg. 2014;259:760–6.  https://doi.org/10.1097/SLA.0000000000000252.CrossRefGoogle Scholar
  45. 45.
    Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57:203–12.  https://doi.org/10.1016/j.jhep.2011.12.034.CrossRefGoogle Scholar
  46. 46.
    Ghabril M, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation. Transplantation. 2016;100:126–33.  https://doi.org/10.1097/TP.0000000000000785.CrossRefGoogle Scholar
  47. 47.
    Urata J, Yamashita Y, Tsuchigame T, Hatanaka Y, Matsukawa T, Sumi S, et al. The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol. 1998;13:1061–7.  https://doi.org/10.1111/j.1440-1746.1998.tb00571.x.CrossRefGoogle Scholar
  48. 48.
    Kamath PS, Lacerda M, Ahlquist DA, McKusick MA, Andrews JC, Nagorney DA. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology. 2000;118:905–11.  https://doi.org/10.1016/S0016-5085(00)70176-4.CrossRefGoogle Scholar
  49. 49.
    Mezawa S, Homma H, Ohta H, Masuko E, Doi T, Miyanishi K, et al. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol. 2001;96:1155–9.  https://doi.org/10.1016/S0002-9270(01)02257-2.CrossRefGoogle Scholar
  50. 50.
    European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.  https://doi.org/10.1016/j.jhep.2015.07.040.CrossRefGoogle Scholar
  51. 51.
    Perelló A, García-Pagán JC, Gilabert R, Suárez Y, Moitinho E, Cervantes F, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132–9.  https://doi.org/10.1053/jhep.2002.30274.CrossRefGoogle Scholar
  52. 52.
    Garcia–Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–15.  https://doi.org/10.1053/j.gastro.2008.05.051.CrossRefGoogle Scholar
  53. 53.
    Seijo S, Plessier A, Hoekstra J, Dell’Era A, Mandair D, Rifai K, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–8.  https://doi.org/10.1002/hep.26306.CrossRefGoogle Scholar
  54. 54.
    • Bissonnette J, Garcia-Pagán JC, Albillos A, Turon F, Ferreira C, Tellez L, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology. 2016;64:224–31.  https://doi.org/10.1002/hep.28547 This retrospective study evaluates the efficacy and safety of TIPS in patients with idiopathic non-cirrhotic portal hypertension. CrossRefGoogle Scholar
  55. 55.
    Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology. 2014;59:2276–85.  https://doi.org/10.1002/hep.26904.CrossRefGoogle Scholar
  56. 56.
    Hernández-Gea V, Baiges A, Turon F, Garcia-Pagán JC. Idiopathic portal hypertension. Hepatology. 2018;68:2413–23.  https://doi.org/10.1002/hep.30132.CrossRefGoogle Scholar
  57. 57.
    Senzolo M, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther. 2006;23:767–75.  https://doi.org/10.1111/j.1365-2036.2006.02820.x.CrossRefGoogle Scholar
  58. 58.
    Qi X, Han G, Yin Z, He C, Wang J, Guo W, et al. Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. Dig Dis Sci. 2012;57:1072–82.  https://doi.org/10.1007/s10620-011-1975-5.CrossRefGoogle Scholar
  59. 59.
    Fanelli F, Angeloni S, Salvatori FM, Marzano C, Boatta E, Merli M, et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis. 2011;43:78–84.  https://doi.org/10.1016/j.dld.2010.06.001.CrossRefGoogle Scholar
  60. 60.
    Luo X, Nie L, Zhou B, Yao D, Ma H, Jiang M, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma. Gastroenterol Res Pract. 2014;2014:1–8.  https://doi.org/10.1155/2014/659726.CrossRefGoogle Scholar
  61. 61.
    Klinger C, Riecken B, Schmidt A, De Gottardi A, Meier B, Bosch J, et al. Transjugular portal vein recanalization with creation of intrahepatic portosystemic shunt (PVR-TIPS) in patients with chronic non-cirrhotic, non-malignant portal vein thrombosis Transjuguläre Pfortaderrekanalisation mit intrahepatischem portosystemischem. Z Gastroenterol. 2018;56:221–37.  https://doi.org/10.1055/s-0043-121348.CrossRefGoogle Scholar
  62. 62.
    Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth H. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant. 2000;25:987–92.  https://doi.org/10.1038/sj.bmt.1702386.CrossRefGoogle Scholar
  63. 63.
    Campos-Varela I, Castells L, Dopazo C, Pérez-Lafuente M, Allende H, Len O, et al. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl. 2012;18:201–5.  https://doi.org/10.1002/lt.22351.CrossRefGoogle Scholar
  64. 64.
    Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41:386–400.  https://doi.org/10.1002/hep.20559.CrossRefGoogle Scholar
  65. 65.
    Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46.  https://doi.org/10.1111/j.1572-0241.2008.02102.x.CrossRefGoogle Scholar
  66. 66.
    Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26:943–51.  https://doi.org/10.1111/j.1440-1746.2011.06663.x.CrossRefGoogle Scholar
  67. 67.
    Wang Q, Lv Y, Bai M, Wang Z, Liu H, He C, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017;67:508–16.  https://doi.org/10.1016/j.jhep.2017.05.006.CrossRefGoogle Scholar
  68. 68.
    Stents P, Miraglia R, Maruzzelli L, Amico MD, Luca A, Tuzzolino F, et al. Portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm. Radiology. 2017;284:281–8.  https://doi.org/10.1148/radiol.2017161644.CrossRefGoogle Scholar
  69. 69.
    Moitinho E, Escorsell À, Bandi J, Salmerón J, García–Pagán J, Rodés J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626–631. doi: https://doi.org/10.1016/S0016-5085(99)70455-5.
  70. 70.
    Bambha K, Kim WR, Pedersen R, Bida JP, Kremers WK, Kamath PS. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut. 2008;57:814–20.  https://doi.org/10.1136/gut.2007.137489.CrossRefGoogle Scholar
  71. 71.
    Lecleire S, Di Fiore F, Merle V, Hervé S, Duhamel C, Rudelli A, et al. Acute upper gastrointestinal bleeding in patients with liver cirrhosis and in noncirrhotic patients: epidemiology and predictive factors of mortality in a prospective multicenter population-based study. J Clin Gastroenterol. 2005;39:321–7.  https://doi.org/10.1097/01.mcg.0000155133.50562.c9.CrossRefGoogle Scholar
  72. 72.
    Ripoll C, Bañares R, Rincón D, Catalina M-V, Lo Iacono O, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era. Hepatology. 2005;42:793–801.  https://doi.org/10.1002/hep.20871.CrossRefGoogle Scholar
  73. 73.
    Thomopoulos K, Theocharis G, Mimidis K, Lampropoulou-Karatza C, Alexandridis E, Nikolopoulou V. Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short- and long-term mortality. Dig Liver Dis. 2006;38:899–904.  https://doi.org/10.1016/j.dld.2006.08.002.CrossRefGoogle Scholar
  74. 74.
    Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, et al. Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology. 2004;39:1623–30.  https://doi.org/10.1002/hep.20236.CrossRefGoogle Scholar
  75. 75.
    Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146:412–419.e3.  https://doi.org/10.1053/j.gastro.2013.10.018.CrossRefGoogle Scholar
  76. 76.
    Bureau C, Métivier S, D’Amico M, Péron JM, Otal P, Pagan JCG, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol. 2011;54:901–7.  https://doi.org/10.1016/j.jhep.2010.08.025.CrossRefGoogle Scholar
  77. 77.
    Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, et al. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology. 2000;118:138–44.  https://doi.org/10.1016/S0016-5085(00)70422-7.CrossRefGoogle Scholar
  78. 78.
    Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104:2458–66.  https://doi.org/10.1038/ajg.2009.321.CrossRefGoogle Scholar
  79. 79.
    Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52:879–85.  https://doi.org/10.1136/gut.52.6.879.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • José Ferrusquía-Acosta
    • 1
  • Virginia Hernández-Gea
    • 1
    • 2
    Email author
  1. 1.Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic de Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain
  2. 2.Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)MadridSpain

Personalised recommendations